Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) has announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., recently obtained a Drug Registration Certificate (Certificate No.: 2026S00307) from the National Medical Products Administration (NMPA) for its Sitagliptin and Metformin Hydrochloride Extended-Release Tablets, granting approval for production.

This medication is indicated for the treatment of adult patients with type 2 diabetes mellitus who are already on a combined therapy of sitagliptin and metformin extended-release tablets.

The drug was initially developed by Merck Sharp & Dohme and was first launched in the United States in 2012.

In June 2024, Changzhou Pharmaceutical Factory submitted an application for registration and market approval for this drug to the NMPA, which was subsequently accepted.

As of the announcement date, the company has invested approximately RMB 8.49 million in research and development costs for this pharmaceutical product.